SRC-JRN S.C.R. 34 75(R)   BILL ANALYSIS


Senate Research Center   S.C.R. 34
By: Moncrief
Health & Human Services
3-19-97
As Filed


DIGEST 

Currently, the federal Food and Drug Administration is charged with the
approval process for new drugs.  The approval process for new drugs,
biological products, and medical devices is slower than the pace of
scientific and medical advances.  This proposal considers measures that
would further improve the FDA's performance in approving new medical
processes. 

PURPOSE

As proposed, S.C.R. 34 submits the following resolutions:

To urge the Congress of the United States to address this important issue
by enacting comprehensive legislation to facilitate the rapid review and
approval of innovative new drugs, biological products, and medical
devices, without compromising patient safety or product effectiveness, and 

To provide that copies of this resolution be prepared and forwarded by the
Texas secretary of state to the President of the United States, the
Speaker of the United States House of Representatives, the President of
the United States Senate, and to all members of the Texas delegation to
the Congress with the request that this resolution be entered in the
Congressional Record as a memorial to the Congress of the United States.